121 related articles for article (PubMed ID: 8306243)
1. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
DeNardo GL; Kroger LA; DeNardo SJ; Miers LA; Salako Q; Kukis DL; Fand I; Shen S; Renn O; Meares CF
Cancer; 1994 Feb; 73(3 Suppl):1012-22. PubMed ID: 8306243
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
DeNardo SJ; Kramer EL; O'Donnell RT; Richman CM; Salako QA; Shen S; Noz M; Glenn SD; Ceriani RL; DeNardo GL
J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
[TBL] [Abstract][Full Text] [Related]
4. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
5. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
6. gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies.
Thomas GE; Esteban JM; Raubitschek A; Wong JY
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):529-34. PubMed ID: 7852116
[TBL] [Abstract][Full Text] [Related]
7. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
Kramer EL; Liebes L; Wasserheit C; Noz ME; Blank EW; Zabalegui A; Melamed J; Furmanski P; Peterson JA; Ceriani RL
Clin Cancer Res; 1998 Jul; 4(7):1679-88. PubMed ID: 9676842
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
[TBL] [Abstract][Full Text] [Related]
10. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
[TBL] [Abstract][Full Text] [Related]
11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
14. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
15. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
[TBL] [Abstract][Full Text] [Related]
16. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
17. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.
Schrier DM; Stemmer SM; Johnson T; Kasliwal R; Lear J; Matthes S; Taffs S; Dufton C; Glenn SD; Butchko G
Cancer Res; 1995 Dec; 55(23 Suppl):5921s-5924s. PubMed ID: 7493371
[TBL] [Abstract][Full Text] [Related]
18. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
19. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates.
Harrison A; Walker CA; Parker D; Jankowski KJ; Cox JP; Craig AS; Sansom JM; Beeley NR; Boyce RA; Chaplin L
Int J Rad Appl Instrum B; 1991; 18(5):469-76. PubMed ID: 1917516
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of intravenously administered 111In- and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs.
Quadri SM; Shao Y; Blum JE; Leichner PK; Williams JR; Vriesendorp HM
Nucl Med Biol; 1993 Jul; 20(5):559-70. PubMed ID: 8358341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
